ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal

AbbVie (ABBV) announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease (PD).The study achieved its primary endpoint, patients who received two fixed doses (5mg and 15mg) of once-daily tavapadon for 26 weeks achieved statistically significant improvement in disease burden. This was measured using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) ...